Across TCGA pan-cancer cohorts, MYT1L mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MYT1L data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MYT1L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYT1L expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

UCEC, LUAD, and CCRCC are the cancer types where MYT1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.454	1.000	.014	8	view →
LUAD	DFS	Median	II,III,IV	0.315	0.970	.038	3	view →
CCRCC	DFS	Median	III,IV	0.965	0.308	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MYT1L tumor-vs-normal RNA expression · all MYT1L data types